Respiratory Syncytial Virus Infections

Respiratory
20
Pipeline Programs
14
Companies
37
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
11
0
6
1
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
267%
Small Molecule
133%
+ 23 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
4 programs
2
1
1
MVA-BN-RSV vaccinePhase 3Vaccine1 trial
MVA-BN-RSVPhase 21 trial
MVA BN RSVPhase 11 trial
MVA-BN-RSVPhase 11 trial
Active Trials
NCT02419391Completed63Est. May 2016
NCT02864628Withdrawn0Est. Oct 2017
NCT02873286Completed420Est. Dec 2018
+1 more trials
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
Suptavumab 30 mg/kgPhase 31 trial
Active Trials
NCT02325791Completed1,177Est. Sep 2017
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
MEDI8897Phase 2/31 trial
Active Trials
NCT03959488Completed925Est. Jan 2023
GS
Gilead SciencesFOSTER CITY, CA
5 programs
2
1
GS-5806Phase 21 trial
GS-5806Phase 1
GS-5806Phase 11 trial
Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of AgeN/A
Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of AgeN/A1 trial
Active Trials
NCT01754428Completed2,432Est. May 2013
NCT01797419Withdrawn0Est. Aug 2013
NCT01756482Completed140Est. Jun 2013
Alnylam Pharmaceuticals
3 programs
3
ALN-RSV01Phase 21 trial
ALN-RSV01Phase 21 trial
ALN-RSV01Phase 21 trial
Active Trials
NCT00496821Completed88Est. Nov 2007
NCT01065935Completed87Est. May 2012
NCT00658086Completed24Est. Jun 2009
DS
Daiichi SankyoChina - Shanghai
1 program
1
VN-0200Phase 21 trial
Active Trials
NCT05547087Completed342Est. Feb 2024
Pfizer
PfizerNEW YORK, NY
3 programs
2
ItraconazolePhase 1Small Molecule5 trials
RV521Phase 11 trial
ABRYSVON/A1 trial
Active Trials
NCT07235397Not Yet Recruiting1Est. Sep 2026
NCT07335419Recruiting12Est. Mar 2026
NCT06541678Completed16Est. Mar 2025
+4 more trials
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
2
D46/NS2/N/ΔM2-2-HindIIIPhase 11 trial
RSV cps2 VaccinePhase 1Vaccine1 trial
Active Trials
NCT03102034CompletedEst. May 2018
NCT01968083CompletedEst. May 2015
Vaxart
VaxartSOUTH SAN FRANCISCO, CA
1 program
1
BTA9881Phase 11 trial
Active Trials
NCT00504907CompletedEst. Dec 2008
Vigonvita
VigonvitaChina - Suzhou
1 program
1
Deuremidevir Hydrobromide for SuspensionPhase 11 trial
Active Trials
NCT06328400CompletedEst. May 2024
Sciwind Biosciences
Sciwind BiosciencesChina - Hangzhou
1 program
1
XW001Phase 11 trial
Active Trials
NCT05642403CompletedEst. Jun 2022
Abbott
AbbottABBOTT PARK, IL
1 program
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in GermanyN/A1 trial
Active Trials
NCT01155193Completed30,804Est. Jul 2016
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in GermanyN/A
M&
Merck & Co.RAHWAY, NJ
1 program
The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of N/A1 trial
Active Trials
NCT05562817Unknown1,200Est. Aug 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Bavarian NordicMVA-BN-RSV vaccine
RegeneronSuptavumab 30 mg/kg
AstraZenecaMEDI8897
Daiichi SankyoVN-0200
Bavarian NordicMVA-BN-RSV
Gilead SciencesGS-5806
Alnylam PharmaceuticalsALN-RSV01
Alnylam PharmaceuticalsALN-RSV01
Alnylam PharmaceuticalsALN-RSV01
PfizerItraconazole
PfizerItraconazole
PfizerItraconazole
VigonvitaDeuremidevir Hydrobromide for Suspension
PfizerItraconazole
PfizerItraconazole

Showing 15 of 37 trials with date data

Clinical Trials (37)

Total enrollment: 59,489 patients across 37 trials

NCT05238025Bavarian NordicMVA-BN-RSV vaccine

MVA-BN-RSV Vaccine Trial

Start: Apr 2022Est. completion: Sep 202320,419 patients
Phase 3Terminated
NCT02325791RegeneronSuptavumab 30 mg/kg

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Start: Jul 2015Est. completion: Sep 20171,177 patients
Phase 3Completed
NCT03959488AstraZenecaMEDI8897

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Start: Jul 2019Est. completion: Jan 2023925 patients
Phase 2/3Completed
NCT05547087Daiichi SankyoVN-0200

A Dose Finding Study of VN-0200

Start: Oct 2022Est. completion: Feb 2024342 patients
Phase 2Completed
NCT02873286Bavarian NordicMVA-BN-RSV

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Start: Sep 2016Est. completion: Dec 2018420 patients
Phase 2Completed
NCT01756482Gilead SciencesGS-5806

Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)

Start: Nov 2012Est. completion: Jun 2013140 patients
Phase 2Completed
NCT01065935Alnylam PharmaceuticalsALN-RSV01

Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Start: Feb 2010Est. completion: May 201287 patients
Phase 2Completed
NCT00658086Alnylam PharmaceuticalsALN-RSV01

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Start: Apr 2008Est. completion: Jun 200924 patients
Phase 2Completed
NCT00496821Alnylam PharmaceuticalsALN-RSV01

Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

Start: Jul 2007Est. completion: Nov 200788 patients
Phase 2Completed
NCT07335419PfizerItraconazole

A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)

Start: Jan 2026Est. completion: Mar 202612 patients
Phase 1Recruiting
NCT06541678PfizerItraconazole

A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.

Start: Dec 2024Est. completion: Mar 202516 patients
Phase 1Completed
NCT06706869PfizerItraconazole

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

Start: Dec 2024Est. completion: Feb 202526 patients
Phase 1Completed
NCT06328400VigonvitaDeuremidevir Hydrobromide for Suspension

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension

Start: Mar 2024Est. completion: May 2024
Phase 1Completed
NCT05822440PfizerItraconazole

A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.

Start: Apr 2023Est. completion: Jul 202312 patients
Phase 1Completed
NCT05745701PfizerItraconazole

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

Start: Feb 2023Est. completion: May 202316 patients
Phase 1Completed
NCT04962022PfizerItraconazole

Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants

Start: Jul 2021Est. completion: Sep 202112 patients
Phase 1Completed
NCT05642403Sciwind BiosciencesXW001

A Study of XW001 in Healthy Adult Subjects

Start: Jan 2021Est. completion: Jun 2022
Phase 1Completed
NCT04065698PfizerRV521

Pharmacokinetics and Safety of RV521 Formulations

Start: Aug 2019Est. completion: Sep 20199 patients
Phase 1Completed
NCT03821493PfizerItraconazole

Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single-Dose of PF-06651600 in Healthy Participants

Start: Feb 2019Est. completion: Jun 201912 patients
Phase 1Completed
NCT03782662PfizerItraconazole

A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants

Start: Nov 2018Est. completion: Mar 2019
Phase 1Completed
NCT03723395PfizerItraconazole

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

Start: Sep 2018Est. completion: Dec 2018116 patients
Phase 1Completed
NCT03460977PfizerItraconazole

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Start: Apr 2018Est. completion: Jul 2029453 patients
Phase 1Recruiting
NCT03121664PfizerItraconazole

A Study To Estimate The Effects Of Itraconazole On Pharmacokinetics Of Pf-06649751 In Healthy Adult Subjects

Start: Apr 2017Est. completion: Sep 201711 patients
Phase 1Completed
NCT03102034Allergy TherapeuticsD46/NS2/N/ΔM2-2-HindIII

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

Start: Apr 2017Est. completion: May 2018
Phase 1Completed
NCT03077607PfizerItraconazole

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Start: Nov 2016Est. completion: Jan 201836 patients
Phase 1Completed
NCT02864628Bavarian NordicMVA-BN-RSV

RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.

Start: Sep 2016Est. completion: Oct 20170
Phase 1Withdrawn
NCT02838264PfizerItraconazole

A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

Start: Aug 2016Est. completion: May 201716 patients
Phase 1Completed
NCT02419391Bavarian NordicMVA BN RSV

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

Start: Aug 2015Est. completion: May 201663 patients
Phase 1Completed
NCT02100553PfizerItraconazole

Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women

Start: Apr 2014Est. completion: Jun 201424 patients
Phase 1Completed
NCT01968083Allergy TherapeuticsRSV cps2 Vaccine

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Start: Oct 2013Est. completion: May 2015
Phase 1Completed
NCT01797419Gilead SciencesGS-5806

Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

Start: May 2013Est. completion: Aug 20130
Phase 1Withdrawn
NCT00504907VaxartBTA9881

Safety Study of Oral BTA9881 to Treat RSV Infection

Start: Jul 2007Est. completion: Dec 2008
Phase 1Completed
NCT00585195PfizerItraconazole

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Start: Apr 2006Est. completion: Jan 2022596 patients
Phase 1Completed
NCT07235397PfizerABRYSVO

Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset

Start: Apr 2026Est. completion: Sep 20261 patients
N/ANot Yet Recruiting
NCT05562817Merck & Co.The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of

The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of Age in Jordan

Start: Nov 2022Est. completion: Aug 20231,200 patients
N/AUnknown
NCT01754428Gilead SciencesSurveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age

Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age

Start: Nov 2012Est. completion: May 20132,432 patients
N/ACompleted
NCT01155193AbbottProspective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany

Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany

Start: Sep 2002Est. completion: Jul 201630,804 patients
N/ACompleted

Related Jobs in Respiratory

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
20h ago

Global Senior Medical Director – Respiratory Pipeline Medical Lead

Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr

Praktikant (m/w/d) Marketing Onkologie

Amgen
Germany - Munich
Yesterday

Sr Product Manager, Monarch (1 of 2)

Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Director Quality Control (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 59,489 patients
14 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Severe Asthma(21)Lung Diseases, Interstitial(19)Pulmonary Fibrosis(15)